Two Hours of In Vivo Lung Perfusion Improves Lung Function in Sepsis-Induced Acute Respiratory Distress Syndrome

Byler, Matthew R.; Haywood, Nathan; Money, Dustin; Zhang, Aimee; Beller, Jared P.; Charles, Eric J.; Chancellor, William Z.; Ta, Huy Q.; Stoler, Mark H.; Mehaffey, J. Hunter; Laubach, Victor E.; Krön, Irving L.; Roeser, Mark E.

doi:10.1053/j.semtcvs.2021.02.034

Cited by 4 publications

(3 citation statements)

References 38 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the study by Mehaffey et al [22], this was likely due to a reduction in pulmonary edema, as indicated by improved wet-to-dry weight ratios. We also observed decreased expression of the pleiotropic cytokine IL-6 [67]. This cytokine is characteristically elevated in the hyperinflammatory subphenotype of ARDS, and has been targeted by monoclonal antibodies in the treatment of ARDS associated with COVID-19 [68,69].…”

Section: Investigations Of Ivlp In Ardsmentioning

confidence: 69%

“…While further studies are needed to determine the optimal timing of IVLP, it is likely within this early phase of ARDS that IVLP will There remains a myriad of questions to be answered, in order to establish the optimal protocol for IVLP in the treatment of ARDS. We have demonstrated improved pulmonary function following IVLP and a 4 h reperfusion period [22,67]. However, the optimal timing of IVLP, as well as the long-term effect of IVLP on lung function beyond 4 h of reperfusion, is yet to be determined.…”

Section: Clinical Translation and Future Direction Of Ivlpmentioning

confidence: 91%

“…Most recently, we performed a study comparing the previously used IVLP perfusion time of 4 h to 2 h of IVLP perfusion [67]. Similar to our previous study, eight adult swine underwent LPS infusion to induce ARDS, and then were randomized to either 4 h IVLP (n = 4) or 2 h IVLP (n = 4) treatment groups.…”

Section: Investigations Of Ivlp In Ardsmentioning

confidence: 99%

See 2 more Smart Citations

Isolated Lung Perfusion in the Management of Acute Respiratory Distress Syndrome

Haywood

Byler

Zhang

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is associated with high morbidity and mortality, and current management has a dramatic impact on healthcare resource utilization. While our understanding of this disease has improved, the majority of treatment strategies remain supportive in nature and are associated with continued poor outcomes. There is a dramatic need for the development and breakthrough of new methods for the treatment of ARDS. Isolated machine lung perfusion is a promising surgical platform that has been associated with the rehabilitation of injured lungs and the induction of molecular and cellular changes in the lung, including upregulation of anti-inflammatory and regenerative pathways. Initially implemented in an ex vivo fashion to evaluate marginal donor lungs prior to transplantation, recent investigations of isolated lung perfusion have shifted in vivo and are focused on the management of ARDS. This review presents current tenants of ARDS management and isolated lung perfusion, with a focus on how ex vivo lung perfusion (EVLP) has paved the way for current investigations utilizing in vivo lung perfusion (IVLP) in the treatment of severe ARDS.

show abstract